Is BridgeBio Pharma, Inc. overvalued or undervalued?

As of 7 November 2019, the valuation grade for BridgeBio Pharma, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently considered overvalued, as evidenced by its negative Price to Book Value of -4.59 and an EV to Sales ratio of 73.65, which are starkly unfavorable compared to industry norms. Additionally, the EV to EBITDA ratio stands at -13.82, further highlighting the company's struggles.
In comparison to its peers, BridgeBio Pharma's valuation metrics are concerning. For instance, BioMarin Pharmaceutical, Inc. has a P/E ratio of 19.19 and an EV to EBITDA of 13.77, while Elanco Animal Health, Inc. shows a P/E of 13.22 and an EV to EBITDA of 11.91, both indicating healthier valuations. Despite BridgeBio's recent stock performance, which has outpaced the S&P 500 with a 1-year return of 54.15% compared to the index's 10.26%, the underlying financial ratios suggest that the company remains overvalued in the current market landscape.